CN105481844A - Pharmaceutical composition for the treatment of hypertension - Google Patents
Pharmaceutical composition for the treatment of hypertension Download PDFInfo
- Publication number
- CN105481844A CN105481844A CN201510893564.7A CN201510893564A CN105481844A CN 105481844 A CN105481844 A CN 105481844A CN 201510893564 A CN201510893564 A CN 201510893564A CN 105481844 A CN105481844 A CN 105481844A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- compound
- treatment
- hypertensive
- hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
The present invention relates to a pharmaceutical composition for the treatment of hypertension. The pharmaceutical composition comprises an effective amount of a compound and a pharmaceutically acceptable carrier. The compound has a structure as below. The compound of the present invention has significant effect on hypertension, and can be developed into a clinically effective novel pharmaceutical composition.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to one and treat hypertensive pharmaceutical composition.
Background technology
Hypertension is a kind of common disease, frequently-occurring disease.Along with the raising of people's living standard, hyperpietic is increasing, and particularly hypertensive crisis, severe hypertension patient numbers are in continuous growth, and for this kind of illness, not only injectable drug is little safely but also effectively clinically.Hypertension affects work and life, and hypertension is again coronary heart disease, the most important Hazard Factor of cerebro-vascular diseases.In infraction, 50% is hyperpietic, and the people of cerebral apoplexy patient 76% has hypertension history.Therefore hypertensive danger is sudden death or disables.Hyperpietic will learn life and take good care of and early treatment, with the development of symptom management.
Summary of the invention
One is the object of the present invention is to provide to treat hypertensive pharmaceutical composition.
In order to realize object of the present invention, the invention provides one and treat hypertensive compound, this compound has having structure:
The present invention also provides one to treat hypertensive pharmaceutical composition, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
Preferably, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
Preferably, described thinner is lactose.
Preferably, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
The present invention also provides the purposes of compound in the hypertensive medicine of preparation treatment, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or thinner.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its composition.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, dispersion medium, coating material, tensio-active agent, antioxidant, sanitas (such as antiseptic-germicide, anti-mycotic agent), isotonic agent, absorption delay agent, salt, sanitas, drug stabilizing agent, tackiness agent, vehicle, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of activeconstituents, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention, for hypertensive Be very effective, can be developed to pharmaceutical composition effectively new clinically.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
Experimental example
The structural formula of target compound is:
Get SPF level SD rat 40, male and female half and half, leave and take 10 rats (male and female half and half) at random as Normal group, all the other 30 rats are as modeling group.Modeling group rat lies on the back with the rat after Chloral Hydrate (0.4ml/100g) intraperitoneal injection of anesthesia of 10% and is fixed on operating table, and cut off belly chaeta, 5% iodophor disinfection, 75% alcohol takes off iodine, covers hole towel.Abdominal cavity is opened along the abdomen median line otch that operates, by aseptic technique, careful blunt separation goes out left renal artery, penetrate chorda serica chirurgicalis sterilis, be that the acupuncture needle of 0.25mm is close to parallel placement with Renal artery blood vessel major axis diameter, extract acupuncture needle out after tightening the Renal artery and acupuncture needle with chorda serica chirurgicalis sterilis, result causes unilateral renal artery stenosis, and offside kidney and artery do not touch.Rats in normal control group is except the not ligation Renal artery, and all the other operation techniques are all the same, as sham operated rats.Postoperative continuous 3d abdominal injection penicillin (3 × 10
4u/d) preventing infection.Each treated animal is all normally raised.
Modeling rat 30 is got, Etomidate100mgkg after modeling 10w
-1intraperitoneal injection of anesthesia, BP-100A full-automatic rat non-invasive blood pressure measuring system tail cover method measures each modeling rat blood pressure, as Hypertensive Rats blood pressure values before administration.Be divided into 3 groups by blood pressure values, be respectively model control group, Captopril tablets group, target compound group, often organize 10, male and female half and half.Its blood pressure is measured, as normal rat blood pressure values before administration with method anesthesia Normal group (sham operated rats) rat tail cover method.
Each administration group according to dosage gastric infusion after grouping, Captopril tablets 0.009gkg
-1, target compound 0.002gkg
-1.Sham operated rats, model control group give equal-volume distilled water with method gavage.Every day 1 time, continuous 4w.The results are shown in following table.
| Group | Systolic pressure (mmHg) | Diastolic pressure (mmHg) |
| Sham operated rats | 125.7±5.62 | 78.56±5.21 |
| Model group | 165.45±7.51 | 118.62±6.39 |
| Captopril group | 132.71±6.03 | 92.34±10.28 |
| Target compound group | 142.8±6.73 | 97.39±9.79 |
Claims (7)
1. treat a hypertensive compound, it is characterized in that, this compound has having structure:
2. treat a hypertensive pharmaceutical composition, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the hypertensive pharmaceutical composition for the treatment of according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
4. the hypertensive pharmaceutical composition for the treatment of according to claim 3, is characterized in that, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
5. the hypertensive pharmaceutical composition for the treatment of according to claim 4, is characterized in that, described thinner is lactose.
6. the hypertensive pharmaceutical composition for the treatment of according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
7. the purposes of compound in the hypertensive medicine of preparation treatment, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510893564.7A CN105481844A (en) | 2015-12-08 | 2015-12-08 | Pharmaceutical composition for the treatment of hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510893564.7A CN105481844A (en) | 2015-12-08 | 2015-12-08 | Pharmaceutical composition for the treatment of hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105481844A true CN105481844A (en) | 2016-04-13 |
Family
ID=55669163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510893564.7A Pending CN105481844A (en) | 2015-12-08 | 2015-12-08 | Pharmaceutical composition for the treatment of hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105481844A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1308536A (en) * | 1998-07-06 | 2001-08-15 | 布里斯托尔-迈尔斯斯奎布公司 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| WO2008156601A1 (en) * | 2007-06-14 | 2008-12-24 | Amgen Inc. | Tricyclic inhibitors of hydroxysteroid dehydrogenases |
| CN101619057A (en) * | 2002-06-24 | 2010-01-06 | 阿卡蒂亚药品公司 | N-substituted piperidine derivatives as serotonin receptor agents |
| US20100094000A1 (en) * | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
| WO2011141848A1 (en) * | 2010-05-11 | 2011-11-17 | Pfizer Inc. | Morpholine compounds as mineralocorticoid receptor antagonists |
-
2015
- 2015-12-08 CN CN201510893564.7A patent/CN105481844A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1308536A (en) * | 1998-07-06 | 2001-08-15 | 布里斯托尔-迈尔斯斯奎布公司 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| CN101619057A (en) * | 2002-06-24 | 2010-01-06 | 阿卡蒂亚药品公司 | N-substituted piperidine derivatives as serotonin receptor agents |
| WO2008156601A1 (en) * | 2007-06-14 | 2008-12-24 | Amgen Inc. | Tricyclic inhibitors of hydroxysteroid dehydrogenases |
| US20100094000A1 (en) * | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
| WO2011141848A1 (en) * | 2010-05-11 | 2011-11-17 | Pfizer Inc. | Morpholine compounds as mineralocorticoid receptor antagonists |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102008480A (en) | Irbesartan-containing composite preparation for treating hypertension | |
| CN102008708B (en) | Ramipril-contained compound preparation for treating hypertension | |
| CN102038687A (en) | Amlodipine and losartan-containing compound preparation for treating hypertension | |
| CN105596324A (en) | Application of naringenin to preparation of drugs for preventing and/or treating aortic dissection | |
| CN105481844A (en) | Pharmaceutical composition for the treatment of hypertension | |
| CN103800341B (en) | The combination medicine of anti-curing oncoma | |
| CN105330676A (en) | Drug combination for treating chronic cardiac failure | |
| CN112569222A (en) | Application of trifluroicaritin in preparation of medicine for improving pain, swelling and motor function | |
| CN112569220A (en) | Application of tetrahydrocannabinol in preparation of medicine for treating pulmonary hypertension and pharmaceutical composition containing tetrahydrocannabinol | |
| CN110935002A (en) | Composition with blood pressure lowering effect and application thereof | |
| CN114177163B (en) | Medicine for treating hypertension | |
| CN103948591B (en) | A kind of slimming agents | |
| TWI533869B (en) | Indication of anthra(2,1-c)(1,2,5)thiadiazole-6,11-dione compound in alleviating pain | |
| CN105622562B (en) | A kind of pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN110403946A (en) | Treat the purposes of chronic hypoxic pulmonary hypertension drug in preparation for Buddhist nun according to Shandong | |
| TW201943423A (en) | Uses of euryale seed extract in inhibiting expression of ICAM-1 gene | |
| CN116650457B (en) | Application of PDK1 inhibitor DCA in treatment of aortic aneurysm and dissection | |
| KR101391551B1 (en) | Pharmaceutical composition for prevention and treatment of heart failure and combined formulation including the same | |
| CN101966190A (en) | Amlodipine and eprosartan-containing compound preparation for treating hypertension | |
| CN101732248B (en) | Metoprolol tartrate injection and preparation method thereof | |
| CN109172815B (en) | Application of the human urokinase-type peptidase in preparation treatment hypertension complicated with hyperlipemia drug | |
| CN105503723A (en) | Pharmaceutical composition for treating coronary heart disease | |
| CN106822123A (en) | A kind of pharmaceutical composition for treating cardiovascular and cerebrovascular disease | |
| CN108524509A (en) | A kind of pharmaceutical composition for treating hypertension | |
| CN114762688A (en) | Application of composition containing cilostazol in cerebrovascular diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160413 |
|
| RJ01 | Rejection of invention patent application after publication |